NasdaqGM - Delayed Quote • USD
Vera Therapeutics, Inc. (VERA)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:20 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, CEO & Director | 910.14k | -- | 1975 |
| Mr. Sean P. Grant M.B.A. | Chief Financial Officer | 642k | -- | 1985 |
| Mr. Joseph R. Young M.B.A. | Senior VP of Finance & Chief Accounting Officer | -- | -- | 1973 |
| Mr. Julien E. Capers J.D. | VP & Head of Legal | -- | -- | -- |
| Ms. Kelly Rauber | VP & Head of Human Resources | -- | -- | -- |
| Mr. Tom Doan | Senior Vice President of Development Operations | -- | -- | 1972 |
| Ms. Lauren Frenz | Chief Business Officer | -- | -- | 1985 |
| Dr. Neeraj Pakala M.B.A., Ph.D. | Senior VP and Head of Product Development & Manufacturing | -- | -- | -- |
| Dr. Kerry Cooper M.D. | Senior Vice President of Medical Affairs | -- | -- | -- |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer | -- | -- | 1968 |
Vera Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 51
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Corporate Governance
Vera Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 04, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Mar 27, 2024S-8: Offering RegistrationsSee Full Filing
- Mar 20, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 29, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 25, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 09, 2024 - May 13, 2024
Vera Therapeutics, Inc. Earnings Call
Related Tickers
ALPN Alpine Immune Sciences, Inc.
64.56
-0.09%
JANX Janux Therapeutics, Inc.
47.39
+0.62%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
MRUS Merus N.V.
45.04
+0.24%
CRNX Crinetics Pharmaceuticals, Inc.
42.12
-0.40%
MOR MorphoSys AG
18.04
-0.50%
DYN Dyne Therapeutics, Inc.
24.73
+4.37%
BHVN Biohaven Ltd.
38.97
+1.12%
KRYS Krystal Biotech, Inc.
156.88
+0.77%
RNA Avidity Biosciences, Inc.
24.36
+2.22%